VIR · Vir Biotechnology
Conviction · Medium · more likely to lead the S&P 500 over the next three months, by a modest margin
Wrong if: a daily close below $10.90
Note written ·
Price against the kill line
Closed 8.6% through its kill line on the 13 November 2026 close.
How to read this
The red mark is the price level of the published kill line: a close through it (a weekly close, on a weekly line) would prove the research note wrong on price. The dot is where the stock closed on 13 November 2026; a dot left of the mark has closed through its line.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close below $10.90, on record since 10 November 2026. The shares are up 6.1% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close below $10.90, under the $11.02 close of 5 November 2026, which would erase the run-up into the ECLIPSE 1 data. An ECLIPSE 3 result showing no clear advantage over bulevirtide, or a safety finding that delays the mid-2027 filing, would also end the case.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 4 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- −0.2
- Revenue, change on a year (%)
- −178.3
- Gross margin (%)
- 100.0
- Operating margin (%)
- 30.7
- Free cash flow, four quarters ($M)
- −142
- Net cash, cash less debt ($M)
- 455
- Enterprise value to sales (×)
- 4.1
- Free-cash-flow yield (%)
- −8.3
All filed numbers
What Vir Biotechnology reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | −0.2 | −178.3 | — | — |
| first filed | 239 | +19582.5 | 100.0 | 30.7 |
| first filed | 0.0 | −101.0 | — | — |
| first filed | 64.1 | +417.8 | — | −74.8 |
| first filed | 0.2 | −89.9 | — | −72267.9 |
| first filed | 1.2 | −60.5 | 99.1 | −9754.3 |
| Pre-tax income ($M) | −96.4 |
| Net income ($M) four quarters: −185 | −96.3 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +21.8 |
| Operating cash flow ($M) | −141 |
| Capital spending ($M) | 0.8 |
| Free cash flow ($M) | −142 |
| Cash and short-term investments ($M) | 455 |
| Debt ($M) | None reported |
| Net cash, cash less debt ($M) no debt reported | 455 |
| Deferred revenue ($M) at 31 December 2025, filed 23 February 2026; −100.0% on a year | 0.0 |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 896 |
| Market value ($M) | 1,706 |
| Enterprise value, market value plus net debt ($M) no debt reported | 1,251 |
| Enterprise value to sales (×) no debt reported | 4.1 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 1.9 |
| Free-cash-flow yield (%) | −8.3 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 9.5% of shares outstanding sold short, 6.9 days of average trading to cover, +8.4% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $42K |
| 12 monthsfrom | $0 | $8.2M |
The thesis
Vir Biotechnology's hepatitis delta regimen met its pivotal ECLIPSE 1 primary endpoint on 8 November 2026, and the shares are more likely than not to beat the S&P 500 over the next three months. The new stock offering adds dilution but does not change the trial result. The ECLIPSE 2 and ECLIPSE 3 toplines, guided to the first quarter of 2027, decide whether the mid-2027 US filing holds.
Vir's 8 November 2026 release reports that 44% of the 83 treated patients reached the combined endpoint at Week 48: undetectable hepatitis delta virus (HDV) RNA plus a normal level of alanine aminotransferase (ALT), a liver enzyme. In the 41 deferred-treatment patients, assessed at Week 12, the rate was 0%. The p-value was below 0.0001.
Vir announced a proposed public offering of common stock on 12 November 2026, with the size not disclosed in the company's announcement as reported by news services. The shares closed at $12.12 on 12 November 2026, down from $13.13 on 11 November 2026. The 9 November 2026 session had closed at $13.64 after the data, with an intraday 52-week high of $14.38.
Three brokers raised or kept targets after the data. Morgan Stanley (Overweight) raised its target to $28 on 10 November 2026. Evercore ISI (Outperform) raised its target to $25 on 10 November 2026. HC Wainwright (Buy) kept its $22 target on 9 November 2026.
Bullish and bearish views on Vir Biotechnology, Inc.
The bull case on Vir Biotechnology, Inc. (VIR), in brief: the primary and key secondary endpoints hit. The bear case: dilution has started.
Bull case
- The primary and key secondary endpoints hit. 44% of treated patients met the combined endpoint against 0% on deferred treatment, and 79% had undetectable virus at Week 48 against 0% (p<0.0001 for both), per Vir's 8 November 2026 release.
- Patients with cirrhosis responded well. Undetectable virus was reached by 85% of cirrhotic patients (n=46) and 73% of non-cirrhotic patients (n=37), per the 8 November 2026 release. Cirrhotic patients are the sickest group.
- Tolerability supports monthly dosing. Vir reported one Grade 3 treatment-related adverse event among 83 treated patients, with no interruptions or discontinuations, per the 8 November 2026 release.
- Regulatory designations are in place. The regimen has Breakthrough Therapy and Fast Track designations from the US Food and Drug Administration (FDA), per the 8 November 2026 release. No chronic hepatitis delta therapy is FDA-approved today.
- Analysts raised targets after the data. Morgan Stanley set $28 and Evercore ISI set $25 on 10 November 2026, and HC Wainwright reiterated $22 on 9 November 2026, per company news feeds.
- The offering adds cash to a funded plan. Vir held $901.3 million in cash, cash equivalents and investments at 30 September 2026, per its Q3 2026 Form 8-K, before $90 million of Gilead upfront consideration. Runway guidance already extended into the second half of 2028 before the new raise.
Bear case
- Dilution has started. Vir announced a proposed public offering of common stock on 12 November 2026, per company news. The shares closed at $12.12 that day, $1.01 under the 11 November 2026 close, and the offering price had not been set in the announcement.
- The combined rate is lower than the virus-only rate. Only 53% of treated patients normalized ALT, against 5% on deferred treatment, per the 8 November 2026 release. Investors judging the regimen on that stricter measure may see a smaller advantage over existing therapy.
- The control arm was measured at a different time. Treated patients were assessed at Week 48 and deferred patients at Week 12, per the release. The head-to-head test against bulevirtide comes in ECLIPSE 3, guided to the first quarter of 2027.
- The shares have already re-rated. The three-month price change is 31.2%, per adjusted daily closes through 12 November 2026, and the last close sits 15.7% below the 52-week high.
- The company has no product revenue. Vir reported a $96.3 million net loss for the third quarter of 2026, per its 8-K filed 4 November 2026.
- Insiders have sold. Vanina de Verneuil, the general counsel, sold 3,750 shares at an average $11.18 on 2 November to 3 November 2026 under a Rule 10b5-1 plan, per an SEC Form 4 filed 4 November 2026.
Price setup
The shares closed at $12.12 on 12 November 2026. That is above the 50-day average of $11.18 and the 200-day average of $9.75, both as of that close and drawn from adjusted daily closes. The 52-week closing low was $5.44 on 19 November 2025.
The path since the data: $11.02 on 5 November 2026, $12.21 on 6 November 2026, $13.64 on 9 November 2026, $13.15 on 10 November 2026, $13.13 on 11 November 2026, then $12.12 on 12 November 2026 as the offering was announced. The close of 5 November 2026 at $11.02 marks where the shares stood before the run-up into the data, and the 50-day average sits just above it.
Astellas paid $10.36 per share for its April 2026 equity stake. Gilead paid $14.16 per share for its Vir shares, which carry standstill and lockup terms. The final offering price sets whether the market treats the raise as a modest discount or a reset.
Catalysts ahead
- ~31 March 2027 (est.): End of the guided first-quarter 2027 window for the ECLIPSE 2 and ECLIPSE 3 toplines. ECLIPSE 3 is the direct test against bulevirtide and ECLIPSE 2 covers switching patients; together they complete the planned global filing package.
- ~30 June 2027 (est.): Planned US FDA submission, mid-2027. A filing on schedule would move the regimen into regulatory review as a candidate for the first FDA-approved hepatitis delta therapy.
What would change the view
A daily close below $10.90, under the $11.02 close of 5 November 2026, which would erase the run-up into the ECLIPSE 1 data. An ECLIPSE 3 result showing no clear advantage over bulevirtide, or a safety finding that delays the mid-2027 filing, would also end the case.
The risks this note tracks, each with what would confirm it:
- The stock offering prices at a deep discount or grows in size, resetting the share price lower and diluting existing holders. Confirmed by: a pricing announcement or prospectus supplement setting the offering price well under the $12.12 close of 12 November 2026, or an upsized deal.
- The 44% combined response rate is read as only a modest advantage once the stricter ALT measure is weighed against existing therapy. Confirmed by: analysts cutting price targets on differentiation grounds, reversing the $28, $25 and $22 targets set on 9 November 2026 and 10 November 2026.
- ECLIPSE 3 shows a narrow or no advantage over bulevirtide, weakening the commercial case. Confirmed by: the first-quarter 2027 ECLIPSE 3 topline reporting no statistically significant advantage on the primary endpoint.
- The filing timeline slips past mid-2027. Confirmed by: Vir moving its guided submission date or its ECLIPSE 2 and 3 topline window in a quarterly report.
- The run-up into and after the data fades further as the offering absorbs demand. Confirmed by: daily closes back at or below the $11.02 close of 5 November 2026.
What it trades with
The shares trade mainly on Vir's own clinical news and financing events. A wider biotech sell-off can still pull them lower between catalysts. Gilead is a partner on Vir's cancer platform and also sells bulevirtide, the drug ECLIPSE 3 tests against, so Vir's success in hepatitis delta competes with one of its own partners. Astellas funds 60% of global VIR-5500 development, which ties part of Vir's value to cancer data on a separate timeline.
The evidence, claim by claim (8)
- ECLIPSE 1 met its primary endpoint: 44% of treated patients reached undetectable HDV RNA plus ALT normalization at Week 48, versus 0% of deferred-treatment patients at Week 12 (p<0.0001). Vir press release, 8 November 2026 · as of
- 79% of treated patients had undetectable HDV RNA at Week 48 versus 0% on deferred treatment; ALT normalized in 53% versus 5%. Vir press release, 8 November 2026 · as of
- ECLIPSE 2 and ECLIPSE 3 data are expected in the first quarter of 2027, supporting a planned comprehensive US FDA submission in mid-2027. Vir press release, 8 November 2026 · as of
- Cash, cash equivalents and investments were approximately $901.3 million at 30 September 2026, excluding $90 million of Gilead upfront consideration; runway guided into the second half of 2028. Vir Form 8-K exhibit, third quarter 2026 results · as of
- Morgan Stanley maintained Overweight and raised its Vir price target to $28; Evercore ISI maintained Outperform and raised its target to $25. Company news feeds, 10 November 2026 · as of
- HC Wainwright reiterated Buy on Vir with a $22 price target. Company news feeds, 9 November 2026 · as of
- Vir announced a proposed public offering of common stock, size not disclosed in the announcement. Company news feeds, 12 November 2026 · as of
- General counsel Vanina de Verneuil sold 3,750 shares at an average $11.18 on 2 November to 3 November 2026 under a Rule 10b5-1 plan. SEC Form 4 filed 4 November 2026 · as of
Sources
Related · shared themes
ZVRA
Zevra Therapeutics
Zevra Therapeutics is modestly more likely to beat the S&P 500 over three months: MIPLYFFA sold $34.0 million in the third quarter of 2026…
KOD
Kodiak Sciences
Kodiak Sciences' shares look more likely to lag the S&P 500 after a 161.8% three-month run that prices in the DAYBREAK win while share…
ABVX
Abivax SA
Abivax's shares are modestly more likely to beat the S&P 500 over three months because the company guides its US obefazimod ulcerative…
BHVN
Biohaven
Biohaven Ltd. is modestly more likely than not to beat the S&P 500 over three months: the SK Biopharmaceuticals licence has cleared US…